NCT07395986

A Multicenter, Randomized, Double-Masked, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of ZOC2017217 in Subjects With Age-Related Cataract

• Status: Enrolling By Invitation
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd. · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, randomized, double-masked, placebo-controlled pilot study conducted in the United States (US) in subjects with age-related cataract in one or both eyes. Approximately 40 subjects with age-related cataract will be stratified by race and Best Corrected Distance Visual Acuity (BCDVA) and randomized (1:1) to active investigational product (IP) or placebo. Subjects will administer their assigned IP in the qualifying eye(s) two times a day (BID) for 24 weeks before being exited from the study. Subjects with new or ongoing ocular adverse events (AEs) at the time of planned study exit will be asked to return 2 weeks later for a safety follow-up evaluation.

Conditions

• Age Related Cataracts

Interventions

Type	Name	Description
DRUG	0.4% ZOC2017217	Active Investigational Product
DRUG	Control	Control

Timeline

• Start date: 2026-02-10
• Primary completion: 2027-03-01
• Completion: 2027-05-01
• First posted: 2026-02-09
• Last updated: 2026-03-24

Locations

13 sites across 1 country: United States

Regulatory

• FDA-regulated drug study